{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:18:10Z","timestamp":1767651490509},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00115-018-0582-5","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T06:25:56Z","timestamp":1534746356000},"page":"1-11","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antipsychotikaassoziierte motorische Symptome bei schizophrenen Psychosen \u2013 Teil\u00a01","Antipsychotic-induced motor symptoms in schizophrenic psychoses\u2014Part\u00a01"],"prefix":"10.1007","volume":"90","author":[{"given":"D.","family":"Hirjak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. M.","family":"Kubera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bienentreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. A.","family":"Thomann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"issue":"7","key":"582_CR1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/08039488.2016.1164245","volume":"70","author":"M Parksepp","year":"2016","unstructured":"Parksepp M et al (2016) Prevalence of neuroleptic-induced movement disorders: an 8\u2011year follow-up study in chronic schizophrenia inpatients. Nord J Psychiatry 70(7):498\u2013502","journal-title":"Nord J Psychiatry"},{"issue":"1","key":"582_CR2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00115-017-0375-2","volume":"89","author":"D Hirjak","year":"2018","unstructured":"Hirjak D et\u00a0al (2018) Genuine motor phenomena in schizophrenic psychoses: theoretical background and definition of context. Nervenarzt 89(1):44\u201350","journal-title":"Nervenarzt"},{"issue":"1","key":"582_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00115-017-0434-8","volume":"89","author":"D Hirjak","year":"2018","unstructured":"Hirjak D et\u00a0al (2018) Genuine motor phenomena in schizophrenia: neuronal correlates and pathomechanisms. Nervenarzt 89(1):27\u201343","journal-title":"Nervenarzt"},{"key":"582_CR4","first-page":"189","volume":"37","author":"RE Burke","year":"1983","unstructured":"Burke RE, Fahn S (1983) Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol 37:189\u2013192","journal-title":"Adv Neurol"},{"issue":"8","key":"582_CR5","first-page":"769","volume":"24","author":"T Hashimoto","year":"1984","unstructured":"Hashimoto T, Shindo M, Yanagisawa N (1984) Treatment of dystonia with high-dosage trihexyphenidyl. Rinsho Shinkeigaku 24(8):769\u2013777","journal-title":"Rinsho Shinkeigaku"},{"issue":"7","key":"582_CR6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.35.7.1066","volume":"35","author":"RE Burke","year":"1985","unstructured":"Burke RE, Fahn S (1985) Serum trihexyphenidyl levels in the treatment of torsion dystonia. Neurology 35(7):1066\u20131069","journal-title":"Neurology"},{"issue":"4","key":"582_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-198508000-00017","volume":"5","author":"ME Wolf","year":"1985","unstructured":"Wolf ME, Koller WC (1985) Tardive dystonia: treatment with trihexyphenidyl. J\u00a0Clin Psychopharmacol 5(4):247\u2013248","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"582_CR8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.36.2.160","volume":"36","author":"RE Burke","year":"1986","unstructured":"Burke RE, Fahn S, Marsden CD (1986) Torsion dystonia: a\u00a0double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36(2):160\u2013164","journal-title":"Neurology"},{"issue":"6","key":"582_CR9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0887-8994(88)90089-6","volume":"4","author":"CY Tsao","year":"1988","unstructured":"Tsao CY (1988) Low-dose trihexyphenidyl in the treatment of dystonia. Pediatr Neurol 4(6):381","journal-title":"Pediatr Neurol"},{"issue":"4","key":"582_CR10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW et al (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a\u00a0prospective, randomized, double-blind controlled trial. Neurology 46(4):1066\u20131072","journal-title":"Neurology"},{"issue":"3","key":"582_CR11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/WNL.51.3.815","volume":"51","author":"JW Brans","year":"1998","unstructured":"Brans JW et\u00a0al (1998) Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl. Neurology 51(3):815\u2013819","journal-title":"Neurology"},{"issue":"3","key":"582_CR12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0887-8994(98)00140-4","volume":"20","author":"FS Pidcock","year":"1999","unstructured":"Pidcock FS, Hoon AH Jr., Johnston MV (1999) Trihexyphenidyl in posthemorrhagic dystonia: motor and language effects. Pediatr Neurol 20(3):219\u2013222","journal-title":"Pediatr Neurol"},{"issue":"6","key":"582_CR13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/NRL.0b013e31822b54d2","volume":"17","author":"BJ Robottom","year":"2011","unstructured":"Robottom BJ, Reich SG (2011) Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review. Neurologist 17(6):340\u2013341","journal-title":"Neurologist"},{"issue":"2","key":"582_CR14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10072-014-1927-x","volume":"36","author":"T Saito","year":"2015","unstructured":"Saito T et\u00a0al (2015) Combination therapy for segmental craniocervical dystonia (Meige syndrome) with aripiprazole, trihexyphenidyl, and botulinum toxin: three cases reports. Neurol Sci 36(2):243\u2013245","journal-title":"Neurol Sci"},{"issue":"6","key":"582_CR15","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1176\/ajp.2006.163.6.1112a","volume":"163","author":"P Desarkar","year":"2006","unstructured":"Desarkar P, Thakur A, Sinha VK (2006) Aripiprazole-induced acute dystonia. Am J Psychiatry 163(6):1112\u20131113","journal-title":"Am J Psychiatry"},{"issue":"1","key":"582_CR16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0303-8467(91)90006-B","volume":"93","author":"NS Oztekin","year":"1991","unstructured":"Oztekin NS et\u00a0al (1991) High dose anticholinergic therapy (biperiden) in dystonia. Clin Neurol Neurosurg 93(1):35\u201337","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"582_CR17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-0447.1983.tb00339.x","volume":"67","author":"T Friis","year":"1983","unstructured":"Friis T, Christensen TR, Gerlach J (1983) Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand 67(3):178\u2013187","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"582_CR18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.870050107","volume":"5","author":"UJ Povlsen","year":"1990","unstructured":"Povlsen UJ, Pakkenberg H (1990) Effect of intravenous injection of biperiden and clonazepam in dystonia. Mov Disord 5(1):27\u201331","journal-title":"Mov Disord"},{"issue":"3","key":"582_CR19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/PEC.0b013e31828547df","volume":"29","author":"MK Kanburoglu","year":"2013","unstructured":"Kanburoglu MK et\u00a0al (2013) Is acute dystonia an emergency? Sometimes, it really is! Pediatr Emerg Care 29(3):380\u2013382","journal-title":"Pediatr Emerg Care"},{"issue":"1","key":"582_CR20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp.57.1.119","volume":"57","author":"O Kastrup","year":"1994","unstructured":"Kastrup O, Gastpar M, Schwarz M (1994) Acute dystonia due to clozapine. J\u00a0Neurol Neurosurg Psychiatr 57(1):119","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"5","key":"582_CR21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00002826-199110000-00012","volume":"14","author":"G Linazasoro","year":"1991","unstructured":"Linazasoro G, Masso JFM, Olasagasti B (1991) Acute dystonia induced by sulpiride. Clin Neuropharmacol 14(5):463\u2013464","journal-title":"Clin Neuropharmacol"},{"issue":"46","key":"582_CR22","first-page":"4714","volume":"66","author":"U Malm","year":"1969","unstructured":"Malm U (1969) Treatment of neuroleptic induced acute dystonia. Lakartidningen 66(46):4714","journal-title":"Lakartidningen"},{"issue":"4","key":"582_CR23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.pnpbp.2006.01.024","volume":"30","author":"M Yumru","year":"2006","unstructured":"Yumru M et\u00a0al (2006) Acute dystonia after initial doses of ziprasidone: a\u00a0case report. Prog Neuropsychopharmacol Biol Psychiatry 30(4):745\u2013747","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"582_CR24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.149.1.42","volume":"149","author":"L Adler","year":"1986","unstructured":"Adler L et al (1986) A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149:42\u201345","journal-title":"Br J Psychiatry"},{"issue":"1","key":"582_CR25","first-page":"21","volume":"23","author":"L Adler","year":"1987","unstructured":"Adler L et\u00a0al (1987) Noradrenergic mechanisms in akathisia: treatment with propranolol and clonidine. Psychopharmacol Bull 23(1):21\u201325","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"582_CR26","first-page":"109","volume":"4","author":"LA Adler","year":"1991","unstructured":"Adler LA et al (1991) Lack of efficacy of d\u2011propranolol in neuroleptic-induced akathisia. Neuropsychopharmacology 4(2):109\u2013115","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"582_CR27","first-page":"283","volume":"29","author":"LA Adler","year":"1993","unstructured":"Adler LA et\u00a0al (1993) A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 29(2):283\u2013286","journal-title":"Psychopharmacol Bull"},{"issue":"9","key":"582_CR28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1176\/ajp.144.9.1250-a","volume":"144","author":"LA Adler","year":"1987","unstructured":"Adler LA et al (1987) Pindolol and propranolol in neuroleptic-induced akathisia. Am J Psychiatry 144(9):1241\u20131242","journal-title":"Am J Psychiatry"},{"issue":"2","key":"582_CR29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0006-3223(88)90094-7","volume":"23","author":"LA Adler","year":"1988","unstructured":"Adler LA et al (1988) Neuroleptic-induced akathisia: propranolol versus benztropine. Biol Psychiatry 23(2):211\u2013213","journal-title":"Biol Psychiatry"},{"issue":"7","key":"582_CR30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.euroneuro.2009.02.006","volume":"19","author":"A Avital","year":"2009","unstructured":"Avital A et al (2009) Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a\u00a0comparative double-blind study. Eur Neuropsychopharmacol 19(7):476\u2013482","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"582_CR31","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/00007611-199112000-00023","volume":"84","author":"A Dorevitch","year":"1991","unstructured":"Dorevitch A, Durst R, Ginath Y (1991) Propranolol in the treatment of akathisia caused by antipsychotic drugs. South Med\u00a0J 84(12):1505\u20131506","journal-title":"South Med J"},{"issue":"5","key":"582_CR32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.149.5.647","volume":"149","author":"JP Dumon","year":"1992","unstructured":"Dumon JP et al (1992) Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 149(5):647\u2013650","journal-title":"Am J Psychiatry"},{"issue":"6","key":"582_CR33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/ajp.144.6.802","volume":"144","author":"B Dupuis","year":"1987","unstructured":"Dupuis B et al (1987) Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 144(6):802\u2013805","journal-title":"Am J Psychiatry"},{"issue":"6","key":"582_CR34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00004714-200112000-00013","volume":"21","author":"T Fischel","year":"2001","unstructured":"Fischel T et al (2001) Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a\u00a0comparative double-blind study. J\u00a0Clin Psychopharmacol 21(6):612\u2013615","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"582_CR35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.genhosppsych.2007.01.009","volume":"29","author":"R Goyal","year":"2007","unstructured":"Goyal R, Chandrasekaran R, Nanda MR (2007) Propranolol-responsive akathisia following acute encephalitis. Gen Hosp Psychiatry 29(3):273\u2013274","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"582_CR36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00002826-198808000-00005","volume":"11","author":"H Hermesh","year":"1988","unstructured":"Hermesh H, Molcho A, Munitz H (1988) Successful propranolol therapy for neuroleptic-induced akathisia resistant to anticholinergic and benzodiazepine drugs. Clin Neuropharmacol 11(4):369\u2013372","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"582_CR37","first-page":"244","volume":"10","author":"M Irwin","year":"1988","unstructured":"Irwin M, Sullivan G, Van Putten T (1988) Propranolol as a\u00a0primary treatment of neuroleptic-induced akathisia. Hillside J Clin Psychiatry 10(2):244\u2013250","journal-title":"Hillside J Clin Psychiatry"},{"issue":"2","key":"582_CR38","first-page":"107","volume":"11","author":"MS Kramer","year":"1989","unstructured":"Kramer MS, Gorkin R, DiJohnson C (1989) Treatment of neuroleptic-induced akathisia with propranolol: a\u00a0controlled replication study. Hillside J Clin Psychiatry 11(2):107\u2013119","journal-title":"Hillside J Clin Psychiatry"},{"issue":"7","key":"582_CR39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0006-3223(88)90260-0","volume":"24","author":"MS Kramer","year":"1988","unstructured":"Kramer MS et al (1988) Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a\u00a0double-blind, placebo-controlled study. Biol Psychiatry 24(7):823\u2013827","journal-title":"Biol Psychiatry"},{"issue":"2\u20133","key":"582_CR40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0278-5846(83)90111-2","volume":"7","author":"AV Kulik","year":"1983","unstructured":"Kulik AV, Wilbur R (1983) Case report of propranolol (Inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor. Prog Neuropsychopharmacol Biol Psychiatry 7(2\u20133):223\u2013225","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"582_CR41","first-page":"1316","volume":"154","author":"I Kurzthaler","year":"1997","unstructured":"Kurzthaler I et al (1997) Propranolol treatment of olanzapine-induced akathisia. Am J Psychiatry 154(9):1316","journal-title":"Am J Psychiatry"},{"issue":"8351","key":"582_CR42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(83)92566-7","volume":"2","author":"JF Lipinski","year":"1983","unstructured":"Lipinski JF et al (1983) Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 2(8351):685\u2013686","journal-title":"Lancet"},{"issue":"3","key":"582_CR43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/ajp.141.3.412","volume":"141","author":"JF Lipinski Jr.","year":"1984","unstructured":"Lipinski JF Jr. et al (1984) Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 141(3):412\u2013415","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"582_CR44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0006-8993(98)00581-2","volume":"802","author":"K Ohashi","year":"1998","unstructured":"Ohashi K et al (1998) Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: possible brain regions responsible for akathisia. Brain Res 802(1\u20132):134\u2013140","journal-title":"Brain Res"},{"issue":"16","key":"582_CR45","first-page":"895","volume":"14","author":"H Petit","year":"1985","unstructured":"Petit H et\u00a0al (1985) Treatment of akathisia of neuroleptics by propranolol. Presse Med 14(16):895\u2013896","journal-title":"Presse Med."},{"issue":"4","key":"582_CR46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-198708000-00034","volume":"7","author":"S Reiter","year":"1987","unstructured":"Reiter S et al (1987) Atenolol and propranolol in neuroleptic-induced akathisia. J\u00a0Clin Psychopharmacol 7(4):279\u2013280","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"582_CR47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-199308000-00004","volume":"16","author":"P Sachdev","year":"1993","unstructured":"Sachdev P, Loneragan C (1993) Intravenous benztropine and propranolol challenges in acute neuroleptic-induced akathisia. Clin Neuropharmacol 16(4):324\u2013331","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"582_CR48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02244343","volume":"113","author":"P Sachdev","year":"1993","unstructured":"Sachdev P, Loneragan C (1993) Intravenous benztropine and propranolol challenges in tardive akathisia. Psychopharmacology (Berl) 113(1):119\u2013122","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"582_CR49","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410180327","volume":"18","author":"R Sandyk","year":"1985","unstructured":"Sandyk R (1985) Propranolol-induced tardive dyskinesia in a\u00a0patient with akathisia. Ann Neurol 18(3):370","journal-title":"Ann Neurol"},{"issue":"4","key":"582_CR50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4088\/PCC.v07n0412b","volume":"7","author":"A Sharma","year":"2005","unstructured":"Sharma A, Madaan V, Petty F (2005) Propranolol treatment for neuroleptic-induced akathisia. Prim Care Companion J Clin Psychiatry 7(4):202\u2013203","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"5","key":"582_CR51","first-page":"303","volume":"21","author":"HL Wang","year":"1988","unstructured":"Wang HL (1988) Propranolol in the treatment of neuroleptic-induced akathisia. Zhonghua Shen Jing Jing Shen Ke Za Zhi 21(5):303\u2013305, 320","journal-title":"Zhonghua Shen Jing Jing Shen Ke Za Zhi"},{"issue":"8355","key":"582_CR52","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(83)90907-8","volume":"2","author":"R Wilbur","year":"1983","unstructured":"Wilbur R, Kulik AV (1983) Propranolol for akathisia. Lancet 2(8355):917","journal-title":"Lancet"},{"issue":"4","key":"582_CR53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00004714-198808000-00009","volume":"8","author":"R Yassa","year":"1988","unstructured":"Yassa R, Iskandar H, Nastase C (1988) Propranolol in the treatment of tardive akathisia: a\u00a0report of two cases. J\u00a0Clin Psychopharmacol 8(4):283\u2013285","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"582_CR54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-1781(84)90098-2","volume":"11","author":"GS Zubenko","year":"1984","unstructured":"Zubenko GS et\u00a0al (1984) Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 11(2):143\u2013149","journal-title":"Psychiatry Res"},{"issue":"Suppl","key":"582_CR55","first-page":"130","volume":"17","author":"N Shams-Alizadeh","year":"2018","unstructured":"Shams-Alizadeh N et al (2018) Effect of vitamin B6 versus propranolol on antipsychotic-induced akathisia: a pilot comparative double-blind study. Iran J Pharm Res 17(Suppl):130\u2013135","journal-title":"Iran J Pharm Res"},{"issue":"5","key":"582_CR56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5694\/j.1326-5377.2002.tb04387.x","volume":"176","author":"BG Girishchandra","year":"2002","unstructured":"Girishchandra BG et al (2002) Mirtazapine-induced akathisia. Med J Aust 176(5):242","journal-title":"Med J Aust"},{"issue":"6","key":"582_CR57","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1345\/aph.1K672","volume":"42","author":"R Hieber","year":"2008","unstructured":"Hieber R, Dellenbaugh T, Nelson LA (2008) Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 42(6):841\u2013846","journal-title":"Ann Pharmacother"},{"issue":"5","key":"582_CR58","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/YIC.0000000000000035","volume":"29","author":"M Poyurovsky","year":"2014","unstructured":"Poyurovsky M et al (2014) Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol 29(5):296\u2013298","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"582_CR59","first-page":"305","volume":"23","author":"M Poyurovsky","year":"2003","unstructured":"Poyurovsky M et al (2003) Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a\u00a0double-blind randomized placebo-controlled pilot study. J\u00a0Clin Psychopharmacol 23(3):305\u2013308","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"582_CR60","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.biopsych.2005.12.007","volume":"59","author":"M Poyurovsky","year":"2006","unstructured":"Poyurovsky M et al (2006) Low-dose mirtazapine: a\u00a0new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 59(11):1071\u20131077","journal-title":"Biol Psychiatry"},{"issue":"5","key":"582_CR61","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1176\/appi.ajp.158.5.819","volume":"158","author":"M Poyurovsky","year":"2001","unstructured":"Poyurovsky M, Weizman A (2001) Mirtazapine for neuroleptic-induced akathisia. Am J Psychiatry 158(5):819","journal-title":"Am J Psychiatry"},{"issue":"2","key":"582_CR62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/S1092852912000181","volume":"16","author":"M Poyurovsky","year":"2011","unstructured":"Poyurovsky M, Weizman R, Weizman A (2011) Mirtazapine\u2014a\u00a0multifunctional drug: low dose for akathisia. CNS Spectr 16(2):63","journal-title":"CNS Spectr."},{"issue":"5","key":"582_CR63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/2045125315601343","volume":"5","author":"SK Praharaj","year":"2015","unstructured":"Praharaj SK et al (2015) Mirtazapine for antipsychotic-induced acute akathisia: a\u00a0systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol 5(5):307\u2013313","journal-title":"Ther Adv Psychopharmacol"},{"issue":"4","key":"582_CR64","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1345\/aph.1G561","volume":"40","author":"S Ranjan","year":"2006","unstructured":"Ranjan S et al (2006) Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 40(4):771\u2013774","journal-title":"Ann Pharmacother"},{"issue":"4","key":"582_CR65","doi-asserted-by":"crossref","first-page":"474","DOI":"10.4103\/0253-7176.168615","volume":"37","author":"D Raveendranathan","year":"2015","unstructured":"Raveendranathan D, Swaminath GR (2015) Mirtazapine induced akathisia: understanding a\u00a0complex mechanism. Indian J Psychol Med 37(4):474\u2013475","journal-title":"Indian J Psychol Med"},{"issue":"4","key":"582_CR66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/01.jcp.0000169621.45443.ac","volume":"25","author":"MS Wilson 2nd","year":"2005","unstructured":"Wilson MS 2nd (2005) Mirtazapine for akathisia in bipolar disorder. J\u00a0Clin Psychopharmacol 25(4):394\u2013395","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"582_CR67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1176\/ajp.144.2.235","volume":"144","author":"LA Adler","year":"1987","unstructured":"Adler LA et al (1987) Clonidine in neuroleptic-induced akathisia. Am J Psychiatry 144(2):235\u2013236","journal-title":"Am J Psychiatry"},{"issue":"2","key":"582_CR68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1017\/S1461145799001376","volume":"2","author":"B Amann","year":"1999","unstructured":"Amann B, Erfurth A, Grunze H (1999) Treatment of tardive akathisia with clonidine: a\u00a0case report. Int J Neuropsychopharmacol 2(2):151\u2013153","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"582_CR69","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199002000-00003","volume":"10","author":"WW Fleischhacker","year":"1990","unstructured":"Fleischhacker WW, Roth SD, Kane JM (1990) The pharmacologic treatment of neuroleptic-induced akathisia. J\u00a0Clin Psychopharmacol 10(1):12\u201321","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"582_CR70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00002018-200022010-00006","volume":"22","author":"CH Miller","year":"2000","unstructured":"Miller CH, Fleischhacker WW (2000) Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 22(1):73\u201381","journal-title":"Drug Saf"},{"issue":"3","key":"582_CR71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2739\/kurumemedj.37.185","volume":"37","author":"T Nishikawa","year":"1990","unstructured":"Nishikawa T et\u00a0al (1990) Treatment of tardive akathisia with clonidine. Kurume Med\u00a0J 37(3):185\u2013187","journal-title":"Kurume Med J"},{"issue":"9","key":"582_CR72","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0006-3223(90)90515-4","volume":"28","author":"P Sachdev","year":"1990","unstructured":"Sachdev P, Chee KY (1990) Pharmacological characterization of tardive akathisia. Biol Psychiatry 28(9):809\u2013818","journal-title":"Biol Psychiatry"},{"issue":"6","key":"582_CR73","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0278-5846(88)90081-4","volume":"12","author":"R Wilbur","year":"1988","unstructured":"Wilbur R, Kulik FA, Kulik AV (1988) Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Prog Neuropsychopharmacol Biol Psychiatry 12(6):849\u2013864","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"582_CR74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0165-1781(84)90040-4","volume":"13","author":"GS Zubenko","year":"1984","unstructured":"Zubenko GS et al (1984) Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 13(3):253\u2013259","journal-title":"Psychiatry Res"},{"issue":"2","key":"582_CR75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00002826-200603000-00002","volume":"29","author":"C Miodownik","year":"2006","unstructured":"Miodownik C et al (2006) Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a\u00a0randomized, double-blind, controlled study. Clin Neuropharmacol 29(2):68\u201372","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"582_CR76","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00004714-199806000-00013","volume":"18","author":"M Poyurovsky","year":"1998","unstructured":"Poyurovsky M, Fuchs C, Weizman A (1998) Low-dose mianserin in treatment of acute neuroleptic-induced akathisia. J\u00a0Clin Psychopharmacol 18(3):253\u2013254","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"582_CR77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004850-199511000-00008","volume":"10","author":"M Poyurovsky","year":"1995","unstructured":"Poyurovsky M et al (1995) Akathisia-like behavior following ECT, and its successful treatment with low-dose mianserin. Int Clin Psychopharmacol 10(4):257\u2013260","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"582_CR78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00004850-199511000-00009","volume":"10","author":"M Poyurovsky","year":"1995","unstructured":"Poyurovsky M et al (1995) Lithium-induced akathisia responds to low-dose mianserin: case report. Int Clin Psychopharmacol 10(4):261\u2013263","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"582_CR79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004850-199506000-00008","volume":"10","author":"M Poyurovsky","year":"1995","unstructured":"Poyurovsky M, Meerovich I, Weizman A (1995) Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psychopharmacol 10(2):111\u2013114","journal-title":"Int Clin Psychopharmacol"},{"key":"582_CR80","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1192\/bjp.174.3.238","volume":"174","author":"M Poyurovsky","year":"1999","unstructured":"Poyurovsky M et al (1999) Treatment of neuroleptic-induced akathisia with the 5\u2011HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 174:238\u2013242","journal-title":"Br J Psychiatry"},{"issue":"5","key":"582_CR81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00004850-199709000-00003","volume":"12","author":"M Poyurovsky","year":"1997","unstructured":"Poyurovsky M, Weizman A (1997) Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int Clin Psychopharmacol 12(5):263\u2013268","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"582_CR82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.eurpsy.2003.12.008","volume":"19","author":"R Stryjer","year":"2004","unstructured":"Stryjer R et\u00a0al (2004) Mianserin for the rapid improvement of chronic akathisia in a\u00a0schizophrenia patient. Eur Psychiatry 19(4):237\u2013238","journal-title":"Eur Psychiatry"},{"issue":"40","key":"582_CR83","first-page":"4474","volume":"97","author":"M Westerlund","year":"2000","unstructured":"Westerlund M (2000) A case report. Improvement in a\u00a0patient with severe akathisia achieved by mianserin. Lakartidningen 97(40):4474","journal-title":"Lakartidningen"},{"issue":"3","key":"582_CR84","first-page":"733","volume":"46","author":"J Horiguchi","year":"1992","unstructured":"Horiguchi J, Nishimatsu O (1992) Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a\u00a0double-blind study. Jpn J Psychiatry Neurol 46(3):733\u2013739","journal-title":"Jpn J Psychiatry Neurol"},{"issue":"1","key":"582_CR85","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0447.1989.tb01308.x","volume":"80","author":"J Horiguchi","year":"1989","unstructured":"Horiguchi J, Nishimatsu O, Inami Y (1989) Successful treatment with clonazepam for neuroleptic-induced akathisia. Acta Psychiatr Scand 80(1):106\u2013107","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"582_CR86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00004714-198912000-00003","volume":"9","author":"S Kutcher","year":"1989","unstructured":"Kutcher S et al (1989) Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a\u00a0double-blind, placebo-controlled study. J\u00a0Clin Psychopharmacol 9(6):403\u2013406","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"582_CR87","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1176\/ajp.144.6.823-a","volume":"144","author":"SP Kutcher","year":"1987","unstructured":"Kutcher SP et al (1987) Clonazepam treatment of adolescents with neuroleptic-induced akathisia. Am J Psychiatry 144(6):823\u2013824","journal-title":"Am J Psychiatry"},{"issue":"3","key":"582_CR88","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00002826-199406000-00003","volume":"17","author":"D Pujalte","year":"1994","unstructured":"Pujalte D et al (1994) A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol 17(3):236\u2013242","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"582_CR89","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000115809","volume":"24","author":"R Sandyk","year":"1985","unstructured":"Sandyk R (1985) Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam. A case report. Eur Neurol 24(4):286\u2013288","journal-title":"Eur Neurol"},{"issue":"3","key":"582_CR90","first-page":"373","volume":"26","author":"CH Miller","year":"1990","unstructured":"Miller CH et al (1990) Treatment of neuroleptic induced akathisia with the 5\u2011HT2 antagonist ritanserin. Psychopharmacol Bull 26(3):373\u2013376","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"582_CR91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0278-5846(92)90076-Q","volume":"16","author":"CH Miller","year":"1992","unstructured":"Miller CH et al (1992) The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 16(2):247\u2013251","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"582_CR92","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.179.1.4","volume":"179","author":"M Poyurovsky","year":"2001","unstructured":"Poyurovsky M, Weizman A (2001) Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a\u00a0new approach to an old problem. Br J Psychiatry 179:4\u20138","journal-title":"Br J Psychiatry"},{"issue":"3","key":"582_CR93","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/jcp.0b013e3180582439","volume":"27","author":"B Baskak","year":"2007","unstructured":"Baskak B et al (2007) The effectiveness of intramuscular biperiden in acute akathisia: a\u00a0double-blind, randomized, placebo-controlled study. J\u00a0Clin Psychopharmacol 27(3):289\u2013294","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"582_CR94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2190\/RAFD-AXDF-RJAD-FL1R","volume":"30","author":"S Hirose","year":"2000","unstructured":"Hirose S, Ashby CR (2000) Intravenous biperiden in akathisia: an open pilot study. Int J Psychiatry Med 30(2):185\u2013194","journal-title":"Int J Psychiatry Med"},{"issue":"10","key":"582_CR95","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/ajp.135.10.1232","volume":"135","author":"D Gagrat","year":"1978","unstructured":"Gagrat D, Hamilton J, Belmaker RH (1978) Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 135(10):1232\u20131233","journal-title":"Am J Psychiatry"},{"issue":"6","key":"582_CR96","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4088\/JCP.v63n0610","volume":"63","author":"S Hirose","year":"2002","unstructured":"Hirose S, Ashby CR (2002) Immediate effect of intravenous diazepam in neuroleptic-induced acute akathisia: an open-label study. J\u00a0Clin Psychiatry 63(6):524\u2013527","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"582_CR97","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/WNF.0b013e3181ee7f63","volume":"33","author":"R Stryjer","year":"2010","unstructured":"Stryjer R et al (2010) Trazodone for the treatment of neuroleptic-induced acute akathisia: a\u00a0placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 33(5):219\u2013222","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"582_CR98","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0006-3223(88)90090-X","volume":"23","author":"T Danel","year":"1988","unstructured":"Danel T, Servant D, Goudemand M (1988) Amitriptyline in the treatment of neuroleptic-induced akathisia. Biol Psychiatry 23(2):186\u2013188","journal-title":"Biol Psychiatry"},{"issue":"3","key":"582_CR99","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/009127007101100308","volume":"11","author":"JT Kelly","year":"1971","unstructured":"Kelly JT, Abuzzahab FS Sr. (1971) The antiparkinson properties of amantadine in drug-induced parkinsonism. J\u00a0Clin Pharmacol New Drugs 11(3):211\u2013214","journal-title":"J Clin Pharmacol New Drugs"},{"issue":"14","key":"582_CR100","first-page":"785","volume":"286","author":"DS Janowsky","year":"1972","unstructured":"Janowsky DS et al (1972) Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism. N\u00a0Engl J Med 286(14):785","journal-title":"N Engl J Med"},{"issue":"4","key":"582_CR101","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1017\/S0033291700045220","volume":"2","author":"RH Mindham","year":"1972","unstructured":"Mindham RH et al (1972) Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism. Psychol Med 2(4):406\u2013413","journal-title":"Psychol Med"},{"issue":"2","key":"582_CR102","first-page":"93","volume":"15","author":"E Ruther","year":"1973","unstructured":"Ruther E, Fussmann-Hegewald M, Eben E (1973) The effect of amantadine on neuroleptic-induced parkinsonism. Act Nerv Super (Praha) 15(2):93","journal-title":"Act. Nerv. Super. (Praha)"},{"issue":"8","key":"582_CR103","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1176\/ajp.133.8.940","volume":"133","author":"WE Fann","year":"1976","unstructured":"Fann WE, Lake CR (1976) Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 133(8):940\u2013943","journal-title":"Am J Psychiatry"},{"key":"582_CR104","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archneur.1961.00450170098012","volume":"5","author":"WH Timberlake","year":"1961","unstructured":"Timberlake WH, Schwab RS, England AC Jr. (1961) Biperiden (Akineton) in Parkinsonism. Arch Neurol 5:560\u2013564","journal-title":"Arch Neurol"},{"issue":"9","key":"582_CR105","first-page":"536","volume":"7","author":"A Lapolla","year":"1965","unstructured":"Lapolla A, Nash LR (1965) Treatment of phenothiazine-induced parkinsonism with biperiden. Curr Ther Res Clin Exp 7(9):536\u2013541","journal-title":"Curr Ther Res Clin Exp"},{"issue":"5","key":"582_CR106","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/030006058000800507","volume":"8","author":"RV Magnus","year":"1980","unstructured":"Magnus RV (1980) A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug-induced Parkinsonism. J\u00a0Int Med Res 8(5):343\u2013346","journal-title":"J Int Med Res"},{"issue":"1","key":"582_CR107","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004850-200401000-00005","volume":"19","author":"T Drimer","year":"2004","unstructured":"Drimer T, Shahal B, Barak Y (2004) Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int Clin Psychopharmacol 19(1):27\u201329","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"582_CR108","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00002826-198708000-00008","volume":"10","author":"Y Wada","year":"1987","unstructured":"Wada Y, Koshino Y, Yamaguchi N (1987) Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication. Clin Neuropharmacol 10(4):370\u2013375","journal-title":"Clin Neuropharmacol"},{"issue":"18","key":"582_CR109","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2174\/1381612043384123","volume":"10","author":"K Burgyone","year":"2004","unstructured":"Burgyone K et al (2004) The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des 10(18):2239\u20132248","journal-title":"Curr Pharm Des"},{"issue":"5","key":"582_CR110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0447.1993.tb03477.x","volume":"88","author":"DB Double","year":"1993","unstructured":"Double DB et\u00a0al (1993) Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand 88(5):381\u2013384","journal-title":"Acta Psychiatr Scand"},{"issue":"579","key":"582_CR111","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1192\/bjp.124.2.151","volume":"124","author":"HA McClelland","year":"1974","unstructured":"McClelland HA et\u00a0al (1974) The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. Br J Psychiatry 124(579):151\u2013159","journal-title":"Br J Psychiatry"},{"issue":"3","key":"582_CR112","first-page":"209","volume":"21","author":"HAB Ben","year":"1995","unstructured":"Ben HAB et\u00a0al (1995) Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal. Encephale 21(3):209\u2013215","journal-title":"Encephale"},{"issue":"2","key":"582_CR113","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-199904000-00009","volume":"19","author":"GS Ungvari","year":"1999","unstructured":"Ungvari GS et al (1999) Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia. J\u00a0Clin Psychopharmacol 19(2):141\u2013148","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"582_CR114","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2002-19831","volume":"35","author":"K Mori","year":"2002","unstructured":"Mori K et\u00a0al (2002) Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry 35(1):6\u201311","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"582_CR115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/2045125314553611","volume":"4","author":"JE Desmarais","year":"2014","unstructured":"Desmarais JE et\u00a0al (2014) Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol 4(6):257\u2013267","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"582_CR116","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pnpbp.2010.08.030","volume":"35","author":"S Ogino","year":"2011","unstructured":"Ogino S et al (2011) Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35(1):78\u201383","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"582_CR117","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archpsyc.1972.01750220084016","volume":"26","author":"CJ Klett","year":"1972","unstructured":"Klett CJ, Caffey E Jr. (1972) Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch Gen Psychiatry 26(4):374\u2013379","journal-title":"Arch Gen Psychiatry"},{"key":"582_CR118","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.neubiorev.2017.06.007","volume":"80","author":"PN Harten van","year":"2017","unstructured":"van Harten PN et\u00a0al (2017) The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment. Neurosci Biobehav Rev 80:476\u2013487","journal-title":"Neurosci Biobehav Rev"},{"issue":"11","key":"582_CR119","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1176\/ajp.135.11.1414","volume":"135","author":"JA Flaherty","year":"1978","unstructured":"Flaherty JA, Lahmeyer HW (1978) Laryngeal-pharyngeal dystonia as a\u00a0possible cause of asphyxia with haloperidol treatment. Am J Psychiatry 135(11):1414\u20131415","journal-title":"Am J Psychiatry"},{"key":"582_CR120","doi-asserted-by":"publisher","DOI":"10.1177\/0706743718777392","author":"D Martino","year":"2018","unstructured":"Martino D et al (2018) Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry. https:\/\/doi.org\/10.1177\/0706743718777392","journal-title":"Can J Psychiatry"},{"key":"582_CR121","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.1961.03040120016004","volume":"175","author":"FJ Ayd Jr.","year":"1961","unstructured":"Ayd FJ Jr. (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175:1054\u20131060","journal-title":"JAMA"},{"issue":"12","key":"582_CR122","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1176\/ajp.151.12.1819","volume":"151","author":"EJ Aguilar","year":"1994","unstructured":"Aguilar EJ et al (1994) Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 151(12):1819\u20131821","journal-title":"Am J Psychiatry"},{"issue":"6","key":"582_CR123","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/JCP.0000000000000411","volume":"35","author":"DM Gardner","year":"2015","unstructured":"Gardner DM et al (2015) Incidence of oculogyric crisis and long-term outcomes with second-generation antipsychotics in a\u00a0first-episode psychosis program. J\u00a0Clin Psychopharmacol 35(6):715\u2013718","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"582_CR124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4088\/JCP.v59n0307","volume":"59","author":"PN Harten van","year":"1998","unstructured":"van Harten PN et al (1998) Cocaine as a\u00a0risk factor for neuroleptic-induced acute dystonia. J\u00a0Clin Psychiatry 59(3):128\u2013130","journal-title":"J Clin Psychiatry"},{"key":"582_CR125","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-18533-5","volume-title":"Bewegungsst\u00f6rungen bei psychischen Erkrankungen","author":"T Jahn","year":"2004","unstructured":"Jahn T (2004) Bewegungsst\u00f6rungen bei psychischen Erkrankungen. Springer, Heidelberg"},{"issue":"Suppl 1","key":"582_CR126","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2000-7583","volume":"33","author":"M Dose","year":"2000","unstructured":"Dose M, Tempel HD (2000) Abuse potential of anticholinergics. Pharmacopsychiatry 33(Suppl 1):43\u201346","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"582_CR127","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2125.2008.03342.x","volume":"67","author":"P Gjerden","year":"2009","unstructured":"Gjerden P, Bramness JG, Slordal L (2009) The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a\u00a0pharmacoepidemiological study. Br J Clin Pharmacol 67(2):228\u2013233","journal-title":"Br J Clin Pharmacol"},{"key":"582_CR128","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJM196002182620708","volume":"262","author":"WH Waugh","year":"1960","unstructured":"Waugh WH, Metts JC Jr. (1960) Severe extrapyramidal motor activity induced by prochlorperazine. Its relief by the intravenous injection of diphenhydramine. N\u00a0Engl J Med 262:353\u2013354","journal-title":"N Engl J Med"},{"issue":"17","key":"582_CR129","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s00213-017-4646-1","volume":"234","author":"M Juncal-Ruiz","year":"2017","unstructured":"Juncal-Ruiz M et al (2017) Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a\u00a06-week randomised study of antipsychotic treatment. Psychopharmacology (Berl) 234(17):2563\u20132570","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"582_CR130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00115-003-1544-z","volume":"75","author":"BG Schimmelmann","year":"2004","unstructured":"Schimmelmann BG et\u00a0al (2004) The initial dysphoric reaction (IDR) to the first dose of neuroleptics. Nervenarzt 75(1):36\u201343","journal-title":"Nervenarzt"},{"issue":"Suppl 3","key":"582_CR131","first-page":"S181","volume":"36","author":"M Lambert","year":"2003","unstructured":"Lambert M et al (2003) Subjective well-being and initial dysphoric reaction under antipsychotic drugs\u2014concepts, measurement and clinical relevance. Pharmacopsychiatry 36(Suppl 3):S181\u201390","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"582_CR132","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.325","volume":"16","author":"L Hansen","year":"2001","unstructured":"Hansen L (2001) A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol 16(7):495\u2013505","journal-title":"Hum Psychopharmacol"},{"key":"582_CR133","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-007713","author":"HM Cheng","year":"2013","unstructured":"Cheng HM, Park JH, Hernstadt Akathisia D (2013) a\u00a0life-threatening side effect of a\u00a0common medication. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2012-007713","journal-title":"BMJ Case Rep."},{"issue":"6","key":"582_CR134","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/JCP.0000000000000412","volume":"35","author":"M Poyurovsky","year":"2015","unstructured":"Poyurovsky M, Weizman A (2015) Treatment of antipsychotic-related akathisia revisited: the role of serotonin 2A receptor antagonists. J\u00a0Clin Psychopharmacol 35(6):711\u2013714","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"582_CR135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0006-3223(95)00354-1","volume":"40","author":"C Botschev","year":"1996","unstructured":"Botschev C et al (1996) Beta 2\u2011receptor density on mononuclear blood cells in patients suffering from neuroleptic-induced akathisia (NIA). Biol Psychiatry 40(3):203\u2013207","journal-title":"Biol Psychiatry"},{"issue":"2","key":"582_CR136","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF00652239","volume":"88","author":"F Muller-Spahn","year":"1986","unstructured":"Muller-Spahn F et al (1986) Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology. Psychopharmacology (Berl) 88(2):190\u2013195","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"582_CR137","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-1781(83)90012-4","volume":"8","author":"WF Gattaz","year":"1983","unstructured":"Gattaz WF et\u00a0al (1983) Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 8(4):243\u2013250","journal-title":"Psychiatry Res"},{"key":"582_CR138","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672\u2013676","journal-title":"Br J Psychiatry"},{"issue":"4","key":"582_CR139","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","volume":"17","author":"TR Barnes","year":"2003","unstructured":"Barnes TR (2003) The Barnes Akathisia Rating Scale\u2014revisited. J\u00a0Psychopharmacol 17(4):365\u2013370","journal-title":"J Psychopharmacol"},{"issue":"13","key":"582_CR140","first-page":"225","volume":"111","author":"K B\u00f6tzel","year":"2014","unstructured":"B\u00f6tzel K, Tronnier V, Gasser T (2014) Differenzialdiagnose und Therapie des Tremors. Dtsch Arztebl 111(13):225\u2013236","journal-title":"Dtsch Arztebl"},{"key":"582_CR141","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-79126-0","volume-title":"Unerw\u00fcnschte Wirkungen von","author":"R Grohmann","year":"1994","unstructured":"Grohmann R, R\u00fcther E (1994) Neuroleptika. In: Psychopharmaka, Grohmann R, Schmidt LG (Hrsg) Unerw\u00fcnschte Wirkungen von. Springer, Berlin, Heidelberg, New York"},{"issue":"12","key":"582_CR142","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1176\/ajp.138.12.1567","volume":"138","author":"T Jellinek","year":"1981","unstructured":"Jellinek T, Gardos G, Cole JO (1981) Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 138(12):1567\u20131571","journal-title":"Am J Psychiatry"},{"key":"582_CR143","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1192\/bjp.143.6.584","volume":"143","author":"LA Baker","year":"1983","unstructured":"Baker LA, Cheng LY, Amara IB (1983) The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 143:584\u2013590","journal-title":"Br J Psychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-018-0582-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T08:46:34Z","timestamp":1693817194000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-018-0582-5"}},"subtitle":["Dystonien, Akathisie und Parkinsonismus","Dystonia, akathisia und parkinsonism"],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s00115-018-0582-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"type":"print","value":"0028-2804"},{"type":"electronic","value":"1433-0407"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"20 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Hirjak, K.M.\u00a0Kubera, S.\u00a0Bienentreu, P.A.\u00a0Thomann und R.C.\u00a0Wolf geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}